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Human immunodeficiency virus type 1 (HIV-1) R5 isolates that predominantly use CCR5 as a coreceptor are
frequently described as macrophage tropic. Here, we compare macrophage tropism conferred by HIV-1 R5
envelopes that were derived directly by PCR from patient tissue. This approach avoids potentially selective
culture protocols used in virus isolation. Envelopes were amplified (i) from blood and semen of adult patients
and (ii) from plasma of pediatric patients. The phenotypes of these envelopes were compared to those conferred
by an extended panel of envelopes derived from brain and lymph node that we reported previously. Our results
show that R5 envelopes vary by up to 1,000-fold in their capacity to confer infection of primary macrophages.
Highly macrophage-tropic envelopes were predominate in brain but were infrequent in semen, blood, and
lymph node samples. We also confirmed that the presence of N283 in the C2 CD4 binding site of gp120 is
associated with HIV-1 envelopes from the brain but absent from macrophage-tropic envelopes amplified from
blood and semen. Finally, we compared infection of macrophages, CD4 T cells, and peripheral blood
mononuclear cells (PBMCs) conferred by macrophage-tropic and non-macrophage-tropic envelopes in the
context of full-length replication competent viral clones. Non-macrophage-tropic envelopes conferred low-level
infection of macrophages yet infected CD4 T cells and PBMCs as efficiently as highly macrophage-tropic
brain envelopes. The lack of macrophage tropism for the majority of the envelopes amplified from lymph node,
blood, and semen is striking and contrasts with the current consensus that R5 primary isolates are generally
macrophage tropic. The extensive variation in R5 tropism reported here is likely to have an important impact
on pathogenesis and on the capacity of HIV-1 to transmit.
Human immunodeficiency virus type 1 (HIV-1) requires in-
teractions with CD4 and a coreceptor, usually CCR5 or
CXCR4, to trigger fusion of viral and cellular membranes and
entry into cells. CXCR4-using (X4) variants can be isolated
from about 50% of AIDS patients and are associated with a
more rapid loss of CD4 T cells and faster disease progression
(1, 8, 30, 36). CXCR4 is more widely expressed on different
CD4 T-cell populations compared to CCR5, and X4 viruses
thus have a broader T-cell tropism (3, 26). Nevertheless, CD4
depletion and AIDS occur in patients from whom only CCR5-
using viruses can be isolated (6, 10). Transmitted viruses are
usually CCR5-using (R5) viruses, and individuals homozygous
for a defective CCR5 gene (32 CCR5) are substantially pro-
tected from infection (5).
HIV-1 isolates that predominantly use CCR5 as a corecep-
tor have been described as R5 or macrophage tropic (2). How-
ever, HIV-1 R5 viruses vary considerably in cell tropism prop-
erties (11, 18, 33). We reported that primary HIV-1 R5 isolates
varied in their capacity to infect primary macrophage cultures
by over 1,000-fold (33). We also first described a subset of
HIV-1 R5 isolates that could infect CD4 T-cell lines via trace
amounts of CCR5 (11), and we recently described HIV-1 R5
envelopes from brain tissues of individuals with neurological
complications that were highly fusigenic and tropic for macro-
phages (27). These latter envelopes are able to exploit low
amounts of CD4 and/or CCR5 for infection and contrast em-
phatically with envelopes from immune tissue (lymph node)
that failed to confer macrophage infection and required higher
amounts of CD4 for infection. Since the capacity to exploit low
levels of CD4 and/or CCR5 conferred a broader tropism for
both T-cell lines and macrophages, we have tentatively termed
these distinct R5 tropisms as narrow/R5 and broad/R5 (27).
The impact of diverse R5 tropism on transmission or patho-
genesis is unknown. Several groups have reported that viral
isolates from late in disease carry an enhanced macrophage
tropism (16, 22, 38) perhaps similar to that conferred by highly
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macrophage-tropic brain envelopes (27). Most studies of HIV
tropism have been carried out using viruses that were isolated
by culture in peripheral blood mononuclear cells (PBMCs).
This procedure is likely to be highly selective, favoring variants
that replicate faster and efficiently infect T cells.
Here, we examine macrophage tropism of 33 envelopes am-
plified from semen and blood of HIV-1 adults and from the
plasma and cerebral spinal fluid (CSF) of HIV-1 pediatric
patients. These envelopes were amplified by PCR directly from
patient material, thus avoiding any viral replication that could
confer mutation. The envelopes amplified were compared with
an extended panel of envelopes from brain and lymph node
samples that were reported previously (27). Brain tissue is
usually protected by the blood brain barrier and contains low
concentrations of neutralizing antibodies. The role of this im-
munoprivileged environment in the evolution of highly mac-
rophage-tropic variants is not known. In addition, HIV in
semen is believed to originate from both immune and nonim-
mune tissue, including seminal vesicles in the testes, the pros-
tate, and the urethra (19), as well as from immune cells that
infiltrate from inflamed tissue (41). Furthermore, the testes
are protected by the testis blood barrier (43) and may also
represent an immunoprivileged environment. Finally, memory
T cells (the main T-cell target for R5 viruses) comprise a
smaller percentage of total T cells in neonates and infants
compared to adults (31, 34). Neonates may thus also represent
a distinct environment for HIV replication compared to adults.
Each of these different environments may influence the evo-
lution of HIV envelope phenotypes.
Here, we show that in contrast to the brain, macrophage-
tropic R5 envelopes are infrequent in semen, blood, and lymph
nodes.
MATERIALS AND METHODS
Cells. HeLa TZM-BL cells were provided by the NIH AIDS Research and
Reference Reagent Program. HeLa cell clones were provided by Navid Madani
(Dana Farber Cancer Institute, Boston, Mass.) and David Kabat (Oregon Health
and Science University, Portland) (29). NP2/CD4/CCR5 and NP2/CD4/CCR3
(35) were provided by Hiroo Hoshino at Gunma University Graduate School of
Medicine, Maebashi, Japan. Primary macrophages, CD4 T cells, and PBMCs
are described below.
Patient samples. HIV-1 envelopes were amplified as part of three separate
studies from (i) blood and semen of adult patients, (ii) plasma and CSF of
pediatric patients, and (iii) brains and lymph nodes of adult patients. Table 1
summarizes the patient material that was used in this study. Semen- and blood-
derived envelopes were from three adults at different disease stages (9). Pediat-
ric-derived envelopes were from plasma taken from early and late disease stages
of three patients. Brain- and lymph node-derived envelopes were from five AIDS
patients with neurological complications and were described previously (27).
PCR amplification of envelopes. Envelope genes were amplified from patient
tissue samples by nested PCR using the Expand High-Fidelity PCR system
(Roche Inc.) or KOD XL DNA polymerase (Novagen Inc.). A nested PCR
protocol was used as described by Gao et al. (15). Outer primers were Env A
(GGC TTA GGC ATC TCC TAT GGC AGG AAG AA) and Env N (CTG CCA
ATC AGG GAA GTA GCC TTG TGT), and inner primers were Env B (AGA
AAG AGC AGA AGA CAG TGG CAA TGA) and Env M (TAG CCC TTC
CAG TCC CCC CTT TTC TTT TA). Conditions for both rounds of PCR were
as follows: first round, 94°C for 45 s, 50°C for 45 s, and 72°C for 4 min (20 cycles);
second round, 94°C for 45 s, 50°C for 45 s, and 72°C for 4 min 15 s (15 cycles).
Brain and lymph node envelopes were amplified from proviral DNA from
autopsy tissue samples as described previously (27). Envelopes from P3, P31 and
P43 were amplified by limiting dilution from proviral DNA from semen and
blood cells (9). Similar procedures were followed to amplify envelopes from
pediatric HIV-1 RNA in plasma following synthesis of envelope cDNA using
SuperScript reverse transcriptase (RT; Invitrogen Inc.). All envelopes were am-
plified using the Expand High-Fidelity PCR system (Roche Inc.) except for
C98-28, C98-67, and S94csf-11 envelopes, which were amplified with KOD XL
DNA polymerase (Novagen Inc.). Most PCR products were first cloned into
pCR-XL-TOPO (Invitrogen Inc.) and then into the pSVIIIenv expression vector
via conserved KpnI sites. For several envelopes, PCR products were digested
with KpnI and ligated directly into pSVIIIenv. Two P43 envelopes (378.2 and
380.1) contained only one of the KpnI sites and were subjected to limited PCR
to reintroduce the second site.
Phylogenetic analysis. All V1 to V3 gp120 env nucleotide sequences were
assembled and aligned using CHROMAS W (37). Sequences were adjusted
manually. All positions with an alignment gap of one or more nucleotides were
excluded. The tree construction was performed from the same distance matrices
with the neighbor-joining algorithm and Kimura two-parameter model (transi-
tion/transversion ratio, 2.0) to estimate the nucleotide distances. Bootstrap anal-
ysis on 1,000 replicates was used to assess the robustness of the tree. The
phylogenetic tree was generated using the program MEGA version 3 (20). The
NL4.3 reference sequence was used as an outgroup.
Production of envelope-positive pseudotype viruses. The env-negative pNL4.3
construct and pSVIIIenv expression vector were described previously (27).
Pseudotype viruses carrying each patient envelope were produced by cotransfec-
tion of Env pSVIIIenv with Env pNL4.3 into 293T cells using calcium phos-
TABLE 1. Details of patients studied
Patient Age Status Diseasestagec
CD4 count
(cells/mm3)
Neurological
involvement Sample(s)
P3 Adult Homosexual B2 330 No Blood, semen
P31 Adult Homosexual C3 130 No Blood, semen
P43 Adult Homosexual A1 620 No Blood, semen
P-1206 Neonate MTCTa C2 1,119 No Plasma
C3 218 Yes Plasma
P-1114 Neonate Sexual A2 660 No Plasma
A2 1,108 No Plasma
C3 46 Yes Plasma
P-1031 Neonate MTCT N1 2,147 No Plasma
C2 250 Yes Plasma, CSF
NA118 Adult IVDUb C3 80 Yes Frontal lobe, lymph node
NA420 Adult Heterosexual C3 12 Yes Frontal lobe, lymph node
NA20 Adult Hemophiliac C3 4 Yes Frontal lobe, lymph node
NA176 Adult IVDU C3 20 Yes Frontal lobe, lymph node
NA353 Adult IVDU C3 2 Yes Frontal lobe
a MTCT, mother-to-child transmission.
b IVDU, intravenous drug user.
c CDC disease stage classification.
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phate. Cell supernatants carrying progeny pseudotype virions were harvested
48 h after transfection, clarified (1,000  g for 10 min), aliquoted, and stored at
152°C.
Replication-competent clones. NA420 B33 and LN85, NA118 LN33, and
NA20 B59 envelopes were subcloned into pNL4.3 using a BbsI site at the start
of the envelope and an XhoI site downstream from the 3 end of the envelope.
LN33 lacked an XhoI site and was cloned via a proximal BlpI site. A version of
NA420 LN85 envelope that contained B33 gp41 sequences was used (27). Rep-
lication competent clones of YU2 (23) and JR-CSF (18) were obtained from the
NIH AIDS Research and Reference Reagent Program.
Preparation of macrophage cultures. Elutriated monocytes (17) provided by
the University of Massachusetts Center for AIDS Research Elutriation Core
were treated with macrophage colony-stimulating factor (R&D Systems) and
cultured for 5 to 7 days before use for virus infections. Alternatively, macro-
phages were prepared from blood monocytes as described previously (32).
Briefly, fresh blood (from volunteer donors) was diluted 1:1 in RPMI 1640
medium and carefully layered onto 15 ml of Ficoll Hypaque (Pharmacia) in a
50-ml Falcon tube and centrifuged at 350  g for 30 min at room temperature.
White cells harvested from the interphase between Ficoll and plasma and me-
dium were washed in RPMI 1640 and resuspended. Cells were then plated onto
a 15-cm-diameter bacterial petri dish with 108 cells in 20 ml. Cells were incubated
for 3 h at 37°C. The adherent cells were then gently washed twice with fresh
RPMI 1640 5% human plasma, before 15 ml RPMI 1640 containing 10% human
plasma was added and cells were incubated at 37°C overnight. The following day
the plates were washed again to remove nonadherent cells. Then fresh media was
added. Cells were allowed to differentiate into macrophages over the next 5 to 7
days. The day prior to infection, the macrophages were washed three times in
versene and incubated at 37°C for 10 minutes to loosen cell attachments. Mac-
rophages were then gently scraped off and resuspended in RPMI 1640 containing
10% human plasma, counted, and seeded into 48-well tissue culture trays at
1.25 105 cells per well.
Preparation of PBMCs and CD4 T cells. PBMCs were prepared from buffy
coats (Research Blood Components LLC.). Briefly, buffy coats were diluted 1:5
in RPMI 1640 and centrifuged onto Ficoll Paque. Leukocytes were removed
from the interface, washed twice in RPMI 1640, and resuspended at 1  106
cells/ml in RPMI 1640 containing 5 g/ml phytohemagglutinin, 10% fetal bovine
serum, and gentamicin. After two days in culture, cells were resuspended in fresh
RPMI 1640 containing 10 units/ml interleukin-2, 10% fetal bovine serum, and
gentamicin. Cells were infected with HIV-1 between 5 and 7 days from the
initiation of culture.
CD4 T cells were purified by negative selection from PBMCs after 5 to 7 days
of culture as described above. Briefly, cells were treated with a cocktail of
antibodies (StemCell Technologies Inc.) and magnetic particles that bind all cells
except CD4 T cells. All cells except CD4 T cells were removed using an
EasySep magnet (StemCell Technologies Inc.). Enriched CD4 T cells (gener-
ally 98% pure) were then seeded into 96-well culture trays at 2  105 cells per
well for immediate infection.
Coreceptor use of HIV-1 envelopes. Coreceptors used by each envelope were
evaluated in cell-cell fusion assays. Cell-cell fusion was tested by cocultivating
appropriate test cells with 293T cells cotransfected with env pSVIIIenv and
Env pNL43. Cell fusion via CCR2b, CCR3, CCR5, CX3CR1, CXCR6, and
GPR15 was tested using GHOST cells. Fusion via CCR3, CCR5, CCR8, GPR1,
APJ, and CXCR4 was tested using NP2/CD4 cells. Coreceptor NP2/CD4 or
GHOST cells were seeded at 8  104 cells per well in 48-well culture dishes and
incubated overnight. 293T cells were transfected as described above and also
incubated overnight. Each transfected 293T cell culture was trypsinized, and 50
l of cells (2  105 cells/ml) was cocultivated with coreceptor-positive NP2/CD4
or GHOST cells. After 6 h of incubation, cocultivations with coreceptor-positive
NP2/CD4 or GHOST cells were washed in phosphate-buffered saline (PBS) and
fixed for 10 min in methanol containing 1% methylene blue, 0.25% basic fuchsin.
Fixed cells were destained in PBS and examined by light microscopy for the
presence of syncytia. We showed previously that cell-cell fusion assays (although
less quantitative) accurately predict coreceptors used by envelope-positive
pseudoviruses (27).
Infection of HeLa/CD4/CCR5 cells and macrophages. All envelope-positive
pseudotyped viruses were titrated onto HeLa TZM-BL cells and primary mac-
rophage cultures. HeLa TZM-BL cells are derived from the JC53 clone of
HeLa/CD4/CCR5 cells (29), which express high levels of both CD4 and CCR5.
HeLa TZM-BL cells contain both -galactosidase and luciferase reporter genes
(40). Infection of HeLa TZM-BL cells was assessed 2 days after infection by
fixing in cold (4°C) 0.5% glutaraldehyde in PBS and then adding 5-bromo-4-
chloro-3-indolyl--galactopyranoside (X-Gal) substrate (Fisher Scientific Com-
pany LLC) at 0.5 mg/ml in PBS containing 3 mM potassium ferrocyanide, 3 mM
potassium ferricyanide, 1 mM magnesium chloride. Infected cells stained blue
after about 1 hour of incubation at room temperature.
HeLa cell clones expressing different levels of CD4 and CCR5 were as follows:
JC53, JC37, and JC10 were reported to express 1.3  105, 1.5  104, and 2  103
CCR5 molecules on the cell surface and were cloned from HI-J, which expressed
4  105 CD4 molecules (29). RC49, RC23, and RC33 were reported to express
8.5  104, 8.7  103, and 3.2  103 CCR5 molecules and were cloned from HI-R
that expressed 104 CD4 molecules (29). These cells were frozen and used over a
period of 10 passages where receptor levels have been confirmed as high, me-
dium, and low by flow cytometry. HeLa clones were treated with DEAE dextran
and infected as described for HeLa TZM-BL cells. Cells were fixed after 3 days
of culture and immunostained for p24 as previously described (7). Briefly, cells
were washed once in PBS and then fixed in cold (20°C) methanol/acetone at a
ratio of 1:1 for 10 min at room temperature. Fixed cell layers were then washed
once with PBS and once with PBS containing 1% fetal calf serum (FCS) before
adding anti-HIV-1 p24 monoclonal antibodies (MAbs 38:96K and EF7; Centre
for AIDS Reagents, United Kingdom). These MAbs were added as hybridoma
cell culture fluid at a 1:1 ratio diluted 1 in 40 in PBS–1% FCS and incubated at
room temperature for at least 1 hour. Cells were washed once in PBS–1% FCS
before incubating for at least 1 h at room temperature with anti-mouse F(ab)2
fragments conjugated to -galactosidase (Southern Biotechnology Associates,
Inc.) at a dilution of 1 in 400 in PBS–1% FCS to detect the first antibody layer.
Cells were then washed once with PBS–1% FCS and twice with PBS. Infected
cells stained blue on addition of X-Gal substrate as described above.
Macrophage infection was evaluated by fixing infected macrophages in meth-
anol-acetone (1:1) 7 days postinfection and immunostaining for intracellular p24
antigen as described above.
The pseudotype viruses prepared are competent only for a single round of
replication. Thus, individual or groups of recently divided, blue-stained cells were
regarded as foci of infection. For replication-competent viruses, well-separated
areas of p24 staining were regarded as foci. Virus infectivity for HeLa cells and
macrophages was estimated as the focus-forming units per milliliter (FFU/ml).
Infection of CD4 T-cell and PBMC cultures. Infectivity titers for CD4 T
cells and PBMCs were estimated using a 50% tissue culture infective dose
(TCID50) approach. Briefly, CD4 T cells and PBMCs cultured for 5 to 7 days
(as described above) were seeded into wells of a 96-well flat-bottomed tissue
culture dish at 2  105 cells in 50 l of growth medium. Fifty-microliter aliquots
of replication-competent virus were added as serial dilutions in replicates of six.
After 7 days of culture, supernatant was harvested and analyzed for RT activity.
TCID50s were calculated using the Karber method (24).
RT enzyme-linked immunosorbent assay. The Lenti-RT activity assay (Cavidi
Tech, Uppsala, Sweden) was used for RT enzyme-linked immunosorbent assay
of supernatants obtained from infected cultures according to the manufacturer’s
instructions.
RESULTS
Sequence analysis of envelopes genes. Envelopes were se-
quenced from V1 to V3. Figure 1 shows a phylogenetic tree of
all envelopes used in this study. Envelopes clustered into
groups representing the different patients.
Coreceptor use of envelopes. Coreceptor use was evaluated
using cell-cell fusion assays. None of the envelopes reported
here used CXCR4. The vast majority of envelopes used CCR3
and CCR5 and efficiently induced cell-cell fusion in NP2/CD4/
CCR3 and NP2/CD4/CCR5 cells. Several pediatric envelopes
(C98-67, J92-18, and J92-39) also weakly used CCR8. As re-
ported previously, NA420 brain envelopes (B13, B33, and B42)
were CCR5 specific. NA20 B59 used a range of coreceptors (27),
while NA20 B503 used CCR8 in addition to CCR3 and CCR5.
Macrophage tropism of envelopes. Envelope-positive virions
harvested 48 h after transfection of 293T cells were titrated on
HeLa TZM-BL cells, which express high levels of CD4 and
CCR5 (29), and on at least two primary macrophage cultures
derived from different donors. Figure 2 shows macrophage
infectivity as a percentage of the titer recorded on HeLa
TZM-BL cells. Thus, the higher the percentage, the higher the
infectivity or tropism for macrophages. Highly macrophage-
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tropic envelopes were rare in blood, semen, and lymph nodes
of adults. In contrast and as we have previously reported,
macrophage-tropic envelopes were predominant in adult brain
tissue. Furthermore, highly macrophage-tropic envelopes were
infrequent in the three pediatric patients. Table 2 shows the
fraction of macrophage-tropic envelopes detected for each site
tested.
Macrophage tropism correlates with the capacity to exploit
low levels of CD4 for infection. The effects of different cell
surface concentrations of CD4 and CCR5 on infection were
tested using a panel of HeLa cell clones that expressed high or
low levels of CD4 and high, medium, or low levels of CCR5
(29). Using these HeLa cell clones, we previously reported that
macrophage tropism correlated with the capacity to infect cells
via low levels of CD4 (27). The same correlation was observed
for the 10 adult blood and semen envelopes studied here (Fig.
2 and 3A). Thus, SQ43 380.1, which infected macrophages,
also infected HeLa/CD4/CCR5 cells via low levels of CD4. In
contrast, other non-macrophage-tropic blood and semen en-
velopes inefficiently infected HeLa/CD4/CCR5 cells via low
levels of CD4.
Envelopes from pediatric plasma that infected macrophages
also infected HeLa/CD4/CCR5 cells with low CD4 more effi-
ciently than most other envelopes (Fig. 3B). One envelope
derived from the CSF of an infected infant with neurological
complications (S94-CSF-11) was highly macrophage tropic and
conferred high infection of HeLa/CD4/CCR5 via low levels of
CD4. The one exception was a non-macrophage-tropic enve-
lope (S92-14) from the plasma of a pediatric patient that con-
ferred relatively efficient infection of HeLa/CD4/CCR5 cells
via low CD4. The capacities of brain and lymph node enve-
lopes to infect the different HeLa cell clones were reported
previously (27). Figure 3C shows an extended version of the
2004 data for comparison. Thus, macrophage-tropic R5 enve-
lopes from brain conferred infection of HeLa cells via low
levels of CD4, while lymph node-derived envelopes conferred
inefficient infection at best.
Infection of primary CD4 T-cell and PBMC cultures. Ex-
periments described above used single-round envelope-posi-
tive pseudovirions and used HeLa TZM-BL cells as a standard
permissive cell line, which expresses high amounts of CD4 and
CCR5. We next tested whether the differences in macrophage
tropism were maintained in the context of replication-compe-
tent viruses that carried brain- and lymph node-derived enve-
lopes, as well as control macrophage-tropic envelope YU2 and
non-macrophage-tropic envelope JR-CSF. We also evaluated
whether the same replication-competent clones could replicate
in cultures of primary CD4 T cells or PBMCs. Replication-
competent clones were titrated on HeLa TZM-BL cells, pri-
mary macrophages, CD4 T cells, and PBMCs. Infectivity
titers for HeLa TZM-BL cells and macrophages were deter-
mined by evaluating FFU, while infectivity for CD4 T cells
and PBMCs was estimated by TCID50 analysis of RT data.
Figure 4A shows that all envelope-positive viruses replicated to
high titer in HeLa TZM-BL and CD4 T cells and PBMCs.
In contrast, non-macrophage-tropic envelopes (NA420 LN85,
NA118 LN33, and JR-CSF) conferred about 100- to 1,000-fold
lower infectivities for primary macrophages compared to highly
macrophage-tropic envelopes (NA420 B33, NA20 B59, and
YU2). Although infectivities for T cells and PBMCs are mea-
FIG. 1. Phylogenetic analysis of the V1 to V3 sequences of enve-
lopes investigated. V1 to V3 gp120 Env sequences were used to con-
struct the phylogenetic tree by the neighbor-joining method. The se-
quence of the NL4.3 virus was used as an outgroup. The percentage of
bootstrap repetitions (out of 1,000) in which the nucleotide sequences
grouped together is represented as a number at the branch node, but
only the bootstrap values of 74% are shown. The genetic distance
was 2%. Envelopes from pediatric patients P-1206, P-1114, and P-1031
are designated by the letters S, C, and J, respectively.
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sured differently than for macrophages and HeLa TZM-BL cells,
it is valuable to compare ratios of infectivity titers for macro-
phages with those recorded on PBMCs and CD4 T cells as
shown in Fig. 4B. Whether macrophage infectivity is compared
to infectivity recorded on HeLa TZM-BL cells, PBMCs, or
CD4 T cells, the ratios conferred by non-macrophage-tropic
JR-CSF, LN33, and LN85 are substantially lower (100- to
1,000-fold) than those conferred by macrophage-tropic enve-
lopes YU2, B59, and B33. We also compared infectivity for
macrophages, PBMCs, and CD4 T cells as ratios of infectivity
recorded on HeLa TZM-BL cells (Fig. 4C). While mac/
TZM-BL ratios for non-macrophage-tropic envelopes were
considerably lower than those for macrophage-tropic enve-
lopes, PBMC/TZM-BL and CD4 T-cell/TZM-BL ratios did
not substantially differ between the tropism groups. These re-
sults confirm the extensive variation in macrophage tropism
but indicate that tropism for CD4 T cells and PBMCs is
similar for highly macrophage-tropic and non-macrophage-
tropic envelopes. Figure 4 also shows that the highly macro-
phage-tropic and non-macrophage-tropic phenotypes are main-
tained in the context of replication-competent viruses and are
FIG. 2. Macrophage tropism of HIV-1 R5 envelopes amplified from patient tissues. Amplified envelopes were cloned into pSVIIIenv and
expressed on HIV-1 particles. Infectivity was titrated on HeLa TZM-BL cells (HeLa/CD4/CCR5; JC53 clone [29]) and on primary macrophages.
Infectivity was assessed by immunostaining in situ and estimating the number of infected cells as described previously (27). Macrophage infectivity
is plotted as a percentage of that recorded on HeLa TZM-BL cells. Light symbols represent envelopes that failed to confer any macrophage
infectivity, i.e., macrophage infectivity was less than the value shown.
TABLE 2. Macrophage tropism and presence of N283
in HIV-1 R5 envelopesa
Study
group Source
No. of
patients
Fraction of
macrophage-
tropic
envelopesd
Frequency
of N283 in
C2 CD4
binding site
Adult Brain, proviral 5 10/11 8/11
Lymph node, proviral 3 0/9 1/9
Blood, proviral 3 0/6 0/6
Semen, proviral 3 1/5 0/5
Pediatric Plasma, RNA 3 4/23 0/23
Controls Macrophage tropicb 4/4 1/4
Non-macrophage tropicc 0/1 0/1
a N283 was present in the C2 CD4 binding site that lies just upstream of the V3
loop, for which the HXBc2 sequence is TDNAKTIIVQLNTSVEINCTRPNNN
TRKRIRIQRGPGRAFVTIGKIGNMRQAHC. T283 is in bold, while residues that
contact CD4 are underlined. The V3 loop is in italics.
b Envelopes SF162, JRFL, AD8, and YU2.
c Envelope JR-CSF.
d Fraction of envelopes that conferred macrophage infectivity of 1% of that
recorded for SF162.
6328 PETERS ET AL. J. VIROL.
FIG. 3. Macrophage-tropic envelopes require less CD4 for infection. HeLa cell clones expressing different CD4 and CCR5 levels (29) were infected with
Env pseudoviruses as described in Materials and Methods. After 72 h, cells were fixed and immunostained for p24 antigen, and foci of infection were counted.
Infectivities for Env pseudotypes prepared with envelopes amplified from adult blood and semen (A) and pediatric plasma (B) are shown. Envelopes that
conferred infection of macrophages (SQ43 380.1, C98-15, C98-18, J92-14, and S94-CSF-11) also conferred infection of HeLa cells expressing low levels of CD4.
(C) Infectivities of an extended panel of brain and lymph node envelopes that were previously reported (27) are shown for comparison. Envelopes from pediatric
patients P-1206, P-1114, and P-1031 are designated by the letters S, C, and J, respectively.
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not an artifactual result of the use of single-round pseudovirion
assays.
Role of N283 in the C2 CD4 binding site. The C2 CD4
binding site lies just upstream from the V3 loop in the enve-
lope. The HXBc2 amino acid sequence spanning this region is
shown in Table 2, footnote a. Residues 279D, 280N, 281A, and
283T were shown to directly contact CD4 in the crystal struc-
ture of gp120 and the CD4 complex (21). An asparagine res-
idue at position 283 in the C2 CD4 binding site has been
reported to occur more frequently in envelopes present in the
brain and to confer a more efficient interaction between gp120
and CD4 (13, 14). Table 2 confirms that N283 was frequent
among the brain-derived macrophage-tropic envelopes exam-
ined here. N283 was absent from pediatric plasma and from
adult semen- and blood-derived envelopes, including those
that conferred macrophage infection. Only one lymph node
envelope (NA20 LN14) contained N283. However, while LN14
clustered phylogenetically with NA20 envelopes from the brain
(Fig. 1), it conferred a non-macrophage-tropic phenotype sim-
ilar to other lymph node-derived envelopes. These observa-
tions confirm the prevalence of N283 in macrophage-tropic
envelopes in brain but indicate that it is not the only determi-
nant of macrophage tropism.
DISCUSSION
Our results show that R5 envelopes vary by up to 1,000-fold
in their capacity to confer infection of blood-derived primary
macrophages. Thus, highly macrophage-tropic envelopes were
found frequently in the brain but infrequently in semen, blood,
and lymph node samples. The lack of macrophage tropism for
the majority of the envelopes amplified from lymph node,
blood, and semen is striking and contrasts with a widely held view
that R5 primary isolates are generally macrophage tropic (2).
In this study, PCR-amplified envelopes were coexpressed
with an Env pNL4.3 construct in 293T cells to produce
pseudovirions capable of just a single round of infection. A
concern is that such pseudovirions may not represent replica-
tion-competent viruses present in vivo and may underestimate
macrophage infection. In control experiments, we have shown
that different patient envelopes assemble onto pseudovirions
with slightly different efficiencies. However, these different as-
sembly efficiencies did not correlate with the extent of macro-
phage infectivity (data not shown). Figure 4 shows that full-
length infectious chimeric clones (based on pNL4.3) that carry
different brain- and lymph node-derived envelopes conferred
the same macrophage-tropic and non-macrophage-tropic phe-
notypes as the corresponding envelope-positive pseudovirions.
Virus produced from 293T cells following transfection of these
infectious clones conferred at least 50-fold higher infectivity
than pseudovirions. Nevertheless, ratios of infectivity for mac-
rophages compared to HeLa TZM-BL cells were up to 1,000-
fold lower for non-macrophage-tropic envelopes compared to
highly macrophage-tropic envelopes from the brain. Thus, the
experiments shown in Fig. 4 strongly support the relevance of
the data generated using envelope-positive pseudovirions but
show that the non-macrophage-tropic envelopes are not neg-
ative for macrophage infection, just very inefficient. It was also
possible that virions budding from 293T cells may lack the
necessary adhesion molecules required for macrophage infec-
FIG. 4. Infectivities of replication-competent viruses carrying
highly macrophage-tropic and non-macrophage-tropic envelopes eval-
uated on HeLa TZM-BL cells, primary macrophages, PBMCs, and
CD4 T cells. A. Infectivity titers of replication-competent viruses
carrying macrophage-tropic (YU2, NA20 B59, and NA420 B33) or
non-macrophage-tropic (JR-CSF, NA420 LN85, and NA118 LN33)
envelopes. Infectivities for HeLa TZM-BL cells and macrophages
were estimated by FFU assays, and the results shown represent aver-
aged FFU counts for duplicate wells from one of several experiments
with similar results. Infectivities for PBMCs and CD4 T cells were
estimated by TCID50 assay, using replicates of six wells, and are rep-
resentative of at least two experiments. B. Ratios of infectivity for
macrophages compared to HeLa TZM-BL cells, PBMCs, and CD4 T
cells. C. Ratios of infectivity for macrophages, PBMCs, and CD4 T
cells compared to HeLa TZM-BL cells.
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tion. However, Bounou et al. reported that virions produced from
293T cells that express ICAM-1 attached to primary macrophages
with similar efficiencies to virions lacking ICAM-1 (4). Bounou et
al. concluded that attachment was conferred by CD4-indepen-
dent and adhesion molecule-independent mechanisms that
likely involve envelope sugars and the macrophage mannose
receptor. This is supported by Nguyen and Hildreth, who
showed that the macrophage mannose receptor was the pre-
dominant mode of attachment to macrophages by HIV parti-
cles (25).
We also evaluated whether brain and lymph node enve-
lopes conferred infection of primary CD4 T-cell and
PBMC cultures. Figure 4 demonstrates that replication-
competent clones carrying non-macrophage-tropic lymph
node envelopes (NA420 LN85 and NA118 LN33) conferred
high levels of infectivity for both CD4 T cells and PBMCs.
These results confirm that non-macrophage-tropic envelopes
amplified from immune tissue are fully competent for replica-
tion in primary CD4 T cells and are not compromised for
infection of primary cell types generally.
The determinants of the distinct R5 tropisms are not yet
fully defined. The presence of N283 is likely to play a major
role in the macrophage tropism of envelopes in the brain.
Dunfee et al. (13) have modeled N283 onto the gp120 struc-
ture (21) and shown that N283 more readily forms a hydrogen
bond with Q40 on CD4 and presumably helps to stabilize the
gp120-CD4 interaction. Regardless, macrophage-tropic enve-
lopes amplified from pediatric patients and from adult semen
did not carry N283, indicating that this residue was not the sole
determinant for macrophage infection. In addition, NA20
LN14 did carry N283 and clustered phylogenetically with
NA20 brain envelopes yet failed to infect macrophages. Thus,
the impact of N283 on macrophage infection can be overcome
by other determinants in envelope. For example, Walter et al.
reported that sequences within the V1V2 loops modulated
macrophage infectivity conferred by chimeric envelopes de-
rived from macrophage-tropic R5 BAL and non-macrophage-
tropic X4 NL4.3 HIV-1 isolates (39). The V1V2 loops sit over
gp120 sites involved in binding coreceptors (42) but may also
occlude the CD4 binding site (28). It is also possible that
glycosylation groups (12), other variable loops, or other struc-
tural alterations may occlude the CD4 binding site. These
protective strategies may reduce the efficiency of gp120-CD4
binding even in the presence of N283.
Neutralizing antibodies that target the CD4 binding site on
gp120 may drive evolution of envelope conformations that
protect this site. Since the brain usually contains lower levels of
neutralizing antibodies compared to immune tissue, this envi-
ronment may allow the evolution of variants that interact ef-
ficiently with CD4 and can replicate in macrophage lineage
cells resident in the brain. Viral replication in PBMC cultures
(in the absence of neutralizing antibodies) during isolation may
also select for variants proficient for macrophage infection;
however, they may not be representative of HIV-1 quasispecies
in vivo.
In this study, we investigated envelopes from multiple sam-
ples and patients rather than multiple envelopes from a few
samples. To this end, we have studied 53 envelopes derived
from 22 samples of 11 patients. For most samples, we were able
to study only one to three envelope clones and therefore have
not extensively sampled the viral population present. It is
therefore possible that highly macrophage-tropic variants are
present at lower frequencies outside the brain, and this will
require a more intensive investigation to evaluate.
The remarkable variation in R5 tropism shown here is likely
to have a profound impact on pathogenesis, as also sug-
gested by Gray et al. (16), and on the efficiency of transmis-
sion, depending on the importance of macrophages or cells
that express low amounts of CD4 as targets for infection in
the new host.
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